Bold Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies. Bold Therapeutics’ lead asset, BOLD-100, is a novel Cancer Resistance Pathway (CRP) inhibitor for the treatment of gastric, pancreatic and other cancers in combination with existing anti-cancer therapies.
For more info about Bold: www.bold-therapeutics.com
LifeSciences BC is a non-profit, industry association which supports and represents the life science community of British Columbia through leadership, investment, advocacy and promotion of our world-class life science community.
LifeSciences BC undertakes numerous initiatives including; local, national and international partnerships helping to facilitate investment and global partnering opportunities while nurturing economic development in B.C. through the life sciences industry.